FDA warns of adverse events with leukemia drug

10/13/2013 | CardiovascularBusiness.com

Following reports of adverse cardiovascular events including fatal heart attack, stroke and advancement of coronary artery disease among patients, the FDA has released a safety communication for the leukemia drug ponatinib. The agency is looking into the issue and has advised clinicians to evaluate the risks and benefits when prescribing the medication.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC